Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU
14 avr. 2023 07h30 HE
|
Incannex Healthcare
MELBOURNE, Australia, April 14, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal...
Mindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
03 avr. 2023 07h00 HE
|
Mindset Pharma Inc.
TORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized,...
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics
28 mars 2023 07h00 HE
|
Mindset Pharma Inc.
TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) today issued a letter to shareholders from James Lanthier, Chief...
Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment
15 mars 2023 07h30 HE
|
Incannex Healthcare
Highlights: Interim analysis of study data to date indicates that there is a greater than 85% chance (>85%, alpha error probability 0.05) of the study showing a statistically significant benefit...
2023 SXSW Conference Hosts Psychedelic Healthcare VC Fund Palo Santo
09 mars 2023 10h19 HE
|
Palo Santo
CHICAGO and NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- As therapeutic applications of psychedelics gain more traction in the mainstream consciousness, psychedelics are a major focus at SXSW 2023,...
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
22 févr. 2023 08h00 HE
|
SciSparc Ltd
Tel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
Ehave Provides Progress Update on its HPPD Study with University of Melbourne
02 févr. 2023 08h30 HE
|
Ehave
MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the "Company"), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, is pleased to...
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
28 déc. 2022 09h00 HE
|
Clearmind Medicine Inc.
Company engaged a leading clinical center in Israel and intends to conduct its first- in- human trial in the United States as well Tel Aviv, Israel / Vancouver, Canada, Dec. 28, 2022 (GLOBE...
FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder
15 déc. 2022 08h00 HE
|
Ehave
MIAMI, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, announced today...
The Addition of Three Mental Health Clinics to Irwin Naturals' Florida Footprint Solidifies the Companies Impact as One of the Fastest-Growing Chains of Mental Health Clinics
09 déc. 2022 07h30 HE
|
Irwin Naturals
LOS ANGELES, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) completed the acquisition of the assets of Clare Clinic, Inc., d/b/a...